Combinatorial drug therapies for cardiovascular diseases offer superior efficacy compared to classical monotherapy by intervening on multiple etiopathogenetic mechanisms simultaneously.
Cardiovascular diseases (CVDs) and cardiovascular risk factors
Combinatorial drug therapies vs Monotherapy
INTRODUCTION: In this article, authors report an inclusive discussion about the combinatorial approach for the treatment of cardiovascular diseases (CVDs) and for counteracting the cardiovascular risk factors. The mentioned strategy was demonstrated to be useful for improving the efficacy of pharmacological treatments and in CVDs showed superior efficacy with respect to the classical monotherapeutic approach. AREAS COVERED: According to this topic, authors analyzed the combinatorial treatments that are available on the market, highlighting clinical studies that demonstrated the efficacy of combinatorial drug strategies to cure CVDs and related risk factors. Furthermore, the review gives an outlook on the future perspective of this therapeutic option, highlighting novel drug targets and disease models that could help the future cardiovascular drug discovery. EXPERT OPINION: The use of specifically designed and increasingly rational and effective drug combination therapies can therefore be considered the evolution of polypharmacy in cardiometabolic and CVDs. This approach can allow to intervene on multiple etiopathogenetic mechanisms of the disease or to act simultaneously on different pathologies/risk factors, using the combinations most suitable from a pharmacodynamic, pharmacokinetic, and toxicological perspective, thus finding the most appropriate therapeutic option.
Building similarity graph...
Analyzing shared references across papers
Loading...
Simone Brogi
University of Pisa
Rita Tabanelli
University of Pisa
Vincenzo Calderone
Electrophysiology
Expert Opinion on Drug Discovery
University of Pisa
Building similarity graph...
Analyzing shared references across papers
Loading...
Brogi et al. (Tue,) conducted a review in Cardiovascular diseases (CVDs) and cardiovascular risk factors. Combinatorial drug therapies vs. Monotherapy was evaluated. Combinatorial drug therapies for cardiovascular diseases offer superior efficacy compared to classical monotherapy by intervening on multiple etiopathogenetic mechanisms simultaneously.
synapsesocial.com/papers/6a2230fec7675eb285970cef — DOI: https://doi.org/10.1080/17460441.2022.2104247